As healthcare professionals, we are witnessing an alarming increase in obesity rates worldwide. This rise is accompanied by a surge in associated comorbidities like type 2 diabetes, cardiovascular diseases, and certain types of cancer. Hence, it is crucial to explore effective strategies for managing obesity.
Behavioral interventions form the cornerstone of obesity management. They involve dietary modifications, physical activity enhancement, and behavioral changes. These interventions can be delivered individually or in groups, face-to-face or remotely. The key is to customize the approach based on patient's needs and preferences.
Pharmacotherapy can be considered in patients with a BMI ≥30 or ≥27 with comorbidities, who have not responded to behavioral interventions. The choice of drug should be guided by the patient's comorbid conditions, potential side effects, and cost. Regular follow-up is essential to monitor efficacy and adverse effects.
Endoscopic and surgical interventions are reserved for patients with severe obesity (BMI ≥40 or ≥35 with comorbidities) who have not responded to non-surgical strategies. While these methods have shown significant weight loss and improvement in comorbid conditions, they are associated with potential complications and require lifelong medical follow-up.
Managing obesity requires an interdisciplinary approach involving dietitians, exercise physiologists, behavioral therapists, pharmacists, and surgeons. This team-based approach ensures comprehensive care, addressing all aspects of obesity.
Obesity management is a complex, multifaceted process requiring a personalized, patient-centered approach. It involves behavioral interventions, pharmacotherapy, endoscopic or surgical interventions, and an interdisciplinary team approach. As healthcare professionals, we need to stay updated with the latest evidence-based strategies to provide optimal care to our patients with obesity.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation